French pharmaceutical organization Servier and biotechnology organization Neurochlore recently announced they are launching phase 3 studies to evaluate the use of Bumetanide in children with autism spectrum disorder (ASD). Bumetanide is classically used to treat fluid retention (edema) and high blood pressure.
The plan for the two six-month studies was recently approved by the Pediatric Committee of the European Medicines Agency, and will monitor the children having Bumetanide administered to them twice daily to evaluate its efficacy and safety in alleviating ASD symptoms. The evaluation will particularly focus on the children’s performance with social communication and interaction, as well as their patterns of behavior.
Servier is an international and independent pharmaceutical company governed by a non-profit foundation, with headquarters in Suresnes, France. Neurochlore is a French biotechnology organization focused on understanding and treating developmental brain disorders.
This was reported by AP News on January 31, 2019.
Contact Information: Servier International, 35 Rue de Verdun, Cedex, Suresnes, 92284 France; 33 1 55 72 32 79; Website: www.servier.com/en/
Contact Information: Neurochlore, Batiment Beret-Delaage, Zone Luminy Biotech, case 922, 13288 Marseille Cedex 09, France; Website: www.neurochlore.fr